• Merck Maintaining Its Lofty Valuation Due To Keytruda Momentum

    Source: Forbes - World / 22 Aug 2017 13:42:09   Eastern Standard Time

    Despite the setback that Merck faced in its Keynote-183 and Keynote-185 trials recently, its cancer drug Keytruda hasn’t lost its momentum this year. To add to that, Merck’s newly launched hepatitis C drug Zepatier and established HPV vaccine Gardasil have been gaining ground. http://www.forbes.com/sites/greatspeculations/2017/08/22/merck-maintaining-its-lofty-valuation-due-to-keytruda-momentum/